These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15024966)

  • 1. Positron emission tomography in central nervous system drug discovery and development.
    Cooper M; Metz J
    Neuroimaging Clin N Am; 2003 Nov; 13(4):851-6, xi. PubMed ID: 15024966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development.
    Burns HD; Hamill TG; Eng WS; Francis B; Fioravanti C; Gibson RE
    Curr Opin Chem Biol; 1999 Aug; 3(4):388-94. PubMed ID: 10419855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography in CNS drug discovery and drug monitoring.
    Piel M; Vernaleken I; Rösch F
    J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization.
    Ghose AK; Ott GR; Hudkins RL
    ACS Chem Neurosci; 2017 Jan; 8(1):147-154. PubMed ID: 27741392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging in Central Nervous System Drug Discovery.
    Gunn RN; Rabiner EA
    Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.
    de Lange EC; Hammarlund-Udenaes M
    Clin Pharmacol Ther; 2015 Apr; 97(4):380-94. PubMed ID: 25670219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives.
    Mauro D; Barbagallo G; D Angelo S; Sannino P; Naty S; Bruno C; Olivieri I; Grembiale RD; Ursini F
    Curr Med Chem; 2018; 25(26):3096-3104. PubMed ID: 28545366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re symposium: "Approaches to optimize the discovery of CNS receptor imaging probes for use in drug discovery and development".
    Waterhouse RN; McCarthy TJ; Collier TL; Burns HD
    Mol Imaging Biol; 2003; 5(6):347-9. PubMed ID: 14667489
    [No Abstract]   [Full Text] [Related]  

  • 10. The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET).
    Banister SD; Manoli M; Kassiou M
    J Labelled Comp Radiopharm; 2013; 56(3-4):215-24. PubMed ID: 24285328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical agents positively and negatively affecting the central nervous system.
    Santamaría A; Díaz-Muñoz M
    Cent Nerv Syst Agents Med Chem; 2010 Dec; 10(4):258. PubMed ID: 21171962
    [No Abstract]   [Full Text] [Related]  

  • 12. Nicotinic acetylcholine receptors and imaging.
    Gündisch D
    Curr Pharm Des; 2000 Jul; 6(11):1143-57. PubMed ID: 10903387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of PET ligand discovery to CNS drug development.
    Schmidt ME; Andrés JI
    Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
    [No Abstract]   [Full Text] [Related]  

  • 14. The central nervous influence of drugs on intraocular pressure.
    Innemee HC; van Zwieten PA
    Rev Pure Appl Pharmacol Sci; 1980; 1(2):107-65. PubMed ID: 6267661
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of molecular imaging in drug discovery and development.
    Hargreaves RJ
    Clin Pharmacol Ther; 2008 Feb; 83(2):349-53. PubMed ID: 18167503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research advances in central nervous system effects of scopolamine and related compounds (author's transl)].
    Bian CF; Wang JH
    Sheng Li Ke Xue Jin Zhan; 1981 Feb; 12(2):139-45. PubMed ID: 7031892
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimizing Central Nervous System Drug Development Using Molecular Imaging.
    Hargreaves RJ; Hoppin J; Sevigny J; Patel S; Chiao P; Klimas M; Verma A
    Clin Pharmacol Ther; 2015 Jul; 98(1):47-60. PubMed ID: 25869938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?
    Barrett JS; McGuire J; Vezina H; Spitsin S; Douglas SD
    J Clin Psychopharmacol; 2013 Dec; 33(6):725-8. PubMed ID: 24100788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS drug development - lost in translation?
    Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
    Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of imaging in proof of concept for CNS drug discovery and development.
    Wong DF; Tauscher J; Gründer G
    Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.